BlackRock Advisors’s Atara Biotherapeutics ATRA Stock Holding History

BlackRock Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$165K	Sell	465 -4	-0.9%	-$1.69K	﹤0.01%	2804
2016 Q3	$251K	Buy	469 +62	+15%	+$33.7K	﹤0.01%	2562
2016 Q2	$229K	Buy	407 +94	+30%	+$45.1K	﹤0.01%	2519
2016 Q1	$149K	Buy	313 +26	+9%	+$11.7K	﹤0.01%	2706
2015 Q4	$189K	Sell	287 -137	-32%	-$104K	﹤0.01%	2597
2015 Q3	$334K	Buy	424 +74	+21%	+$90.3K	﹤0.01%	2452
2015 Q2	$461K	Buy	350 +156	+80%	+$179K	﹤0.01%	2235
2015 Q1	$202K	Buy	194 +91	+88%	+$60.1K	﹤0.01%	2663
2014 Q4	$69K	Buy	+103	New	+$62.9K	﹤0.01%	3197

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors's ATRA Position: Q4 2016 in Review

BlackRock Advisors reduced its Atara Biotherapeutics (ATRA) stake by 0.85% in Q4 2016, selling an estimated $1.69K and leaving 465 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #2804.

BlackRock Advisors first reported a position in ATRA in Q4 2014 and has held it in 9 quarters since. The position peaked at $461K in Q2 2015. 85 funds tracked by Wall St. Rank hold ATRA as of Q4 2016.

BlackRock Advisors held 465 shares of Atara Biotherapeutics worth $165K as of Q4 2016.
BlackRock Advisors sold 4 Atara Biotherapeutics shares in Q4 2016, an estimated $1.69K.
Atara Biotherapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2804 holding.
BlackRock Advisors first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 9 quarters since.
BlackRock Advisors's Atara Biotherapeutics position peaked at $461K in Q2 2015.
85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.